Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial

Vaccine

Volumn 30, Issue 31, 2012, Pages 4655-4660

  Pleguezuelos, Olga ^a   Robinson, Stuart ^a   Stoloff, Gregory A ^a   Caparrós Wanderley, Wilson ^a  

^a SEEK   (United Kingdom)

Author keywords

Antibody immunity; Cellular immunity; Clinical trial; Influenza; Safety; Synthetic polypeptides; Vaccine

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; INFLUENZA VACCINE; PLACEBO;

ADULT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CHILL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; LOW DRUG DOSE; MALAISE; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; T LYMPHOCYTE; VOMITING;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-GAMMA; MALE; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84861963299     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.089     Document Type: Article

References (35)

1. Levy E. French economic evaluations of influenza and influenza vaccination. Pharmacoeconomics 1996, 9(Suppl. 3):62-66.
2. Falsey A.R., Cunningham C.K., Barker W.H., Kouides R.W., Yuen J.B., Menegus M., et al. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. Journal of Infectious Diseases 1995, 172:389-394.
3. Taubenberger J.K., Morens D.M. 1918 Influenza: the mother of all pandemics. Emerging Infectious Diseases 2006, 12(1):15-22.
4. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003, 21:1776-1779.
5. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infectious Diseases 2011.
6. Chua J.V., Chen W.H. Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks. Critical Care 2010, 14(2):218.
7. Lambert L.C., Fauci A.S. Influenza vaccines for the future. New England Journal of Medicine 2010, 363(21):2036-2044.
8. Kreijtz J.H., Fouchier R.A., Rimmelzwaan G.F. Immune responses to influenza virus infection. Virus Research 2011, 162(1-2):19-30.
9. Stoloff G.A., Caparrós-Wanderley W. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. European Journal of Immunology 2007, 37:2441-2449.
10. + T-cell memory. Journal of Virology 2000, 74:11690-11696.
11. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259:1745-1749.
12. Jackson D.C., Lau Y.F., Le T., Suhrbier A., Deliyannis G., Cheers C., et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:15440-15445.
13. Graham M.B., Braciale T.J. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. Journal of Experimental Medicine 1997, 186:2063-2068.
14. Chenna R., Sugawara H., Koike T., Lopez R., Gibson T.J., Higgins D.G., et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Research 2003, 31(13):3497-3500.
15. Atsmon J., Kate-Ilovitz E., Shaikevich D., Singer Y., Volokhov I., Haim K.Y., et al. Safety and immunogenicity of multimeric-001-a novel universal Influenza vaccine. Journal of Clinical Immunology 2012.
16. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clinical Cancer Research 2008, 14(1):169-177.
17. Kakimi K., Isobe M., Uenaka A., Wada H., Sato E., Doki Y., et al. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. International Journal of Cancer 2011, 129(12):2836-2846.
18. Rosenberg S.A., Yang J.C., Kammula U.S., Hughes M.S., Restifo N.P., Schwarz S.L., et al. Different adjuvanticity of incomplete Freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine. Journal of Immunotherapy 2010, 33(6):626-629.
19. Diefenbach C.S., Gnjatic S., Sabbatini P., Aghajanian C., Hensley M.L., Spriggs D.R., et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clinical Cancer Research 2008, 14(9):2740-2748.
20. Pinto L.A., Berzofsky J.A., Fowke K.R., Little R.F., Merced-Galindez F., Humphrey R., et al. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS 1999, 13(15):2003-2012.
21. Graham B.S., McElrath M.J., Keefer M.C., Rybczyk K., Berger D., Weinhold K.J., et al. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS One 2010, 5(8):e11995.
22. Wu Y., Ellis R.D., Shaffer D., Fontes E., Malkin E.M., Mahanty S., et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 2008, 3(7):e2636.
23. Evans D., Cauchemez S., Hayden F.G. 'Prepandemic' immunization for novel influenza viruses, 'swine flu' vaccine, Guillain-Barré syndrome, and the detection of rare severe adverse events. Journal of Infectious Diseases 2009, 200:321-328.
24. + memory T cells specific for a subdominant epitope following Sendai virus infection. Journal of Immunology 1997, 158:4301-4309.
25. Oukka M., Manuguerra J.C., Livaditis N., Tourdot S., Riche N., Vergnon I., et al. Protection against lethal viral infection by vaccination with nonimmunodominant peptides. Journal of Immunology 1996, 157:3039-3045.
26. Rockman S., Brown L. Pre-pandemic and pandemic influenza vaccines. Human Vaccine 2010, 6(10):792-801.
27. + T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clinical Infectious Diseases 2011, 52(1):1-7.
28. Dormitzer P.R., Galli G., Castellino F., Golding H., Khurana S., Del Giudice G., et al. Influenza vaccine immunology. Immunological Reviews 2011, 239(1):167-177.
29. Deng Y., Jing Y., Campbell A.E., Gravenstein S. Age-related impaired type 1T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. Journal of Immunology 2004, 172(6):3437-3446.
30. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. Journal of Immunology 2006, 176(10):6333-6339.
31. Bernstein E., Kaye D., Abrutyn E., Gross P., Dorfman M., Murasko D.M. Immune response to influenza vaccination in a large healthy elderly population. Vaccine 1999, 17(1):82-94.
32. Gardner E.M., Gonzalez E.W., Nogusa S., Murasko D.M. Age-related changes in the immune response to influenza vaccination in a racially diverse: healthy elderly population. Vaccine 2006, 24(10):1609-1614.
33. Monto A.S., Ansaldi F., Aspinall R., McElhaney J.E., Montaño L.F., Nichol K.L., et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine 2009, 7(37):5043-5053.
34. Mcmichael A.J., Dongworth D.W., Gotch F.M., Clark A., Potter C.W. Declining T cell immunity to Influenza: 1977-82. The Lancet 1983, 322(8353):762-764.
35. Thomas P.G., Keating R., Hulse-Post D.J., Doherty P.C. Cell-mediated protection in influenza infection. Emerging Infectious Diseases 2006, 12(1):48-54.